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S U M M A R Y
Patients recovered from Ebola virus infection may experience short- and long-term physical,
neuropsychological and social sequelae, including arthralgia, musculoskeletal pain, ophthalmic
inﬂammation, auditory problems, fatigue, confusion, insomnia, short-term memory impairment,
anxiety, depression and anorexia, all lasting from two weeks to more than two years. Currently there are
no treatments for post Ebola sequelae. We hypothesize that cannabidiol (CBD) may attenuate some of
these post Ebola sequelae, several of which have been postulated to result from inﬂammation and/or an
autoimmune response. CBD has anti-inﬂammatory actions in various animal models. Clinical studies
have shown that oral administration of CBD, compared to placebo, signiﬁcantly reduces anxiety, has
antinociceptive and anticonvulsant actions, and may be therapeutic for insomnia. Overall, CBD has a
number of pharmacological effects that may signiﬁcantly improve the mental and somatic health of
patients suffering from post Ebola sequelae. In humans, CBD, at therapeutic doses, does not: 1) elicit
dependence or tolerance; 2) signiﬁcantly alter heart rate or blood pressure; 3) affect gastrointestinal
transit; 4) produce signiﬁcant cognitive or psychomotor impairments. Mild sedation and nausea are the
most commonly reported adverse effects associated with CBD.CBD, based on its pharmacological effects
and favorable safety proﬁle, should be considered as a treatment for individuals with post Ebola
sequelae.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j idData suggest that individuals who fully recover from Ebola virus
infection (absence of initial Ebola symptoms and virus-free blood
samples) may experience sequelae of short-term and long-term
physical, neuropsychological, and social problems. The occurrence
of post Ebola sequelae was ﬁrst suggested in a report published in
1976 indicating that survivors from an Ebola virus epidemic in
South Sudan experienced pain and weakness 6–8 weeks after
discharge from a hospital.1
Following the current Ebola epidemic in West Africa (beginning
December 2013), it has been estimated that there may be 16 000–
17 000 Ebola survivors.2 A wide range of post Ebola clinical
manifestations have been reported, including arthralgia, musculo-
skeletal pain, ophthalmic disease (uveitis, blurred vision, conjunc-
tivitis, hyperlacrimation, photophobia, pain), fatigue or malaise,
headache, anorexia, auditory problems (hearing loss, tinnitus),
impairment of short term memory, confusion, difﬁculty in* Corresponding author.
E-mail address: cnsratdoc@optonline.net (C.R. Ashby Jr).
http://dx.doi.org/10.1016/j.ijid.2016.09.020
1201-9712/ 2016 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).sleeping, anxiety, psychosocial distress, anemia, skin disorders,
alopecia, and various constitutional symptoms that can last from
2 weeks to more than 2 years.3–7 It has been reported that
neurological disabilities can be observed in nearly all patients at
6 months after survival from infection (n = 82; 50% of survivors had
severe manifestations).8 A certain percentage of Ebola survivors
have reported that their ongoing health problems interfere with
normal activity and work, which decreases their quality of life.
Furthermore, Ebola survivors are subjected to stigmatization after
returning to their community.
All species of Ebola virus that elicit disease in humans (Sudan,
Zaire, Tai Forest, Bundibugyo) produce post Ebola syndrome.
However, because the majority of studies in Ebola survivors have
been uncontrolled, one cannot deﬁnitely attribute Ebola virus
infection to the above-mentioned sequelae. There has been no
rigorous determination of the long-term consequences in
survivors of Ebola virus infection, and the percentage of
individuals with sequelae after infection is unknown. In addition,
the criteria and deﬁnition of post Ebola syndrome have not been
established.ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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time frame and symptomatology that is associated with post Ebola
syndrome. It should be noted that the symptoms experienced by
Ebola survivors could result, in part, from (1) previous infection
with other viruses common to the Ebola outbreak area, such as
malaria, dengue fever, and Lassa virus; (2) the development of
post-traumatic stress; (3) a prolonged recovery from the illness.
The pathogenesis of post Ebola syndrome is unknown, but it has
been postulated to result from (1) damage produced during the
infectious period; (2) immune recognition of viral antigens in
tissues, producing autoimmune-like manifestations, including
inﬂammation; (3) the persistence of the virus (for weeks to
months) in certain protected tissues/organs (i.e., anterior chamber
of the eye, testes, brain); (4) a sustained immune response.
Currently, there are no treatments for this syndrome.
Based on pharmacological studies in animals and humans, it was
hypothesized that cannabidiol (CBD), a phytocannabinoid com-
pound from Cannabis sativa, may ameliorate or attenuate some of
the signs/symptoms associated with post Ebola syndrome. CBD has
been reported to produce anti-inﬂammatory actions in animal
models of arthritis, colitis, neurodegenerative diseases, ischemia
reperfusion, asthma, and diabetes.9 Interestingly, animal studies
suggest that systemic CBD signiﬁcantly decreases inﬂammation and
damage due to diabetic retinopathy in rats.10 In addition, the
systemic administration of CBD in various rodent species is active in
models of depression.11 Clinical studies in humans have shown that
the oral administration of CBD, compared to placebo, signiﬁcantly
reduces anxiety, has anti-nociceptive and anticonvulsant actions,
and may be therapeutic for insomnia.12 CBD at 1–25 mM
(signiﬁcantly higher than CBD concentrations obtained after oral
dosing in humans) has been shown not to affect the viability of
numerous non-tumor or normal cell lines in vitro.13 In contrast, CBD
has been shown to have anti-proliferative and anti-apoptotic effects
in various tumor cell lines in vitro.13 Thus, CBD has a number of
pharmacological effects that may improve the mental and physical
health of patients diagnosed with post Ebola syndrome.
The efﬁcacy of CBD could be determined by contacting
individuals 18 years of age or older who have a conﬁrmed history
of Ebola disease, using a randomized, double-blind, placebo-
controlled study design. If CBD treatment is hypothesized to
produce a signiﬁcant improvement in 50% of patients (with a 95%
conﬁdence interval of 40–60%), 100 subjects in the control and CBD
groups would be sufﬁcient to detect a statistically signiﬁcant effect
(p < 0.05). The participants must have had a resolution of
symptoms before discharge and a negative PCR test for Ebola
after discharge. In addition, patients would need to be tested for
malaria, HIV, Lassa virus, chikungunya, and dengue fever, as these
diseases can produce some of the signs/symptoms seen in Ebola
survivors. The individuals in the study would rate their mean
severity of retro-orbital pain, blurred vision, muscle weakness,
joint stiffness, hearing loss, arthralgia, difﬁculty sleeping, fatigue,
headache, dizziness, and anorexia, as well as current limitations in
physical activity, based on the data collection method of Clark
et al.,6 before treatment and after 1 and 3 months of treatment.
CBD (purity of at least 98%, synthetic or natural) would be given
orally, starting at 100 mg/day and slowly titrating up to 600 mg/
day. This dose has been reported to have therapeutic effects in
humans.14
Patients would be monitored for adverse effects. Overall, it is
expected that the proposed dose of CBD would be well tolerated
because, in humans, it does not produce serious or signiﬁcant
adverse or toxic effects. Speciﬁcally, it does not (1) elicit
dependence or tolerance; (2) signiﬁcantly alter heart rate or blood
pressure; (3) affect gastrointestinal transit; (4) produce signiﬁcant
cognitive or psychomotor impairments. In humans, CBD is
tolerable up to doses of 1500 mg per day for 2 weeks.13 Inaddition, CBD at 300 mg/day orally for 3–18 weeks or for 126 days
in patients involved in clinical trials did not produce toxicity or
adverse effects.14 Mild sedation and nausea are the most
commonly reported adverse effects associated with CBD.12 If
CBD were to produce intolerable or severe adverse effects or
increase mortality, treatment would be promptly discontinued.
In vitro and in vivo studies in animals suggest that CBD, at high
concentrations or doses, has immunosuppressive actions.9,13
However, the dose of CBD proposed for Ebola survivors here
would produce low plasma and tissue concentrations. Further-
more, CBD does not increase mortality in animals infected with
certain strains of viruses and bacteria; on the contrary, animal
survival is increased and tissue inﬂammation is decreased.15
Indeed, if the post Ebola sequelae are due in part to an autoimmune
reaction, CBD could well have a therapeutic effect. There are no
published reports of CBD producing diseases or health problems
associated with immunosuppression. Finally, CBD does not have
abuse liability in animals or humans; in fact, CBD can decrease the
appetitive properties of cocaine, morphine, and tobacco.16
CBD has a large volume of distribution (32 l/kg) and can be
found in many tissues and organs, including the eyes and brain.17
CBD is a substrate for human cytochrome P (CYP) 450 2C19 and
3A4 and a potential substrate for CYP3A5, CYP2C9, and UDP-
glucuronosyltransferase isoforms 1A9, 2B7, and 2B17.18 CBD, in
vitro, inhibits a number of human CYP450 isoforms.18 However,
this is unlikely to be clinically signiﬁcant as the half maximal
inhibitory concentration (IC50) values are signiﬁcantly higher than
the concentrations of CBD obtained after oral administration. Data
suggest that drugs that potently induce (e.g., rifampicin) or inhibit
(e.g., ketoconazole) CYP450, signiﬁcantly decrease and increase,
respectively, CBD plasma levels. CBD, in vitro, inhibits the ATP
binding cassette multidrug resistance-related protein 1 (MRP1 or
ABCC1), although the clinical signiﬁcance of this effect is
unknown.19 Currently, studies are lacking regarding drug–drug
interactions for CBD in humans; therefore, monitoring of patients
for potential drug–drug interactions would be required. CBD
should not be used by women who are breast feeding, as it is
concentrated in breast milk, or by those who are pregnant or
considering conception.
In conclusion, it is hypothesized that CBD, based on its
pharmacological effects and favorable safety proﬁle, should be
considered as a treatment for individuals with post Ebola
syndrome.
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